Description

Reltecimod (CAS 1447799-33-8) is an investigational synthetic peptide known for its immunomodulatory properties. It functions as a selective modulator of the immune system, particularly influencing T-cell activity and cytokine production. Reltecimod has been studied in clinical research contexts for treating inflammatory and autoimmune conditions, such as sepsis, by dampening excessive immune activation while preserving host defense.

Manufactured under GMP guidelines with a purity of 99.88%, Reltecimod offers consistent quality and reliability for experimental applications. It is used extensively in immunological research to explore therapeutic potentials in modulating immune responses, inflammation, and cytokine signaling pathways. This product supports wholesale and retail orders exclusively for laboratory research and development.

Product Specifications

Mechanism of Action & Research Applications

Reltecimod selectively modulates the immune system by influencing T-cell responses and cytokine release patterns. It has been explored in research for treating sepsis and other inflammatory disorders by reducing harmful hyperinflammatory states while maintaining immune defense. The compound serves as a valuable tool in immunological research for studying immune regulation, therapeutic modulation of cytokine storms, and inflammation control.

Side Effects (For Reference Only)

Reltecimod is intended exclusively for experimental research. No established clinical toxicity profile exists outside controlled research environments. Standard laboratory safety precautions should be observed to minimize exposure risks.

Disclaimer

This product is intended only for laboratory research purposes. It is not approved for clinical or therapeutic use in humans or animals. Users must comply with institutional and regulatory safety guidelines.